Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SEELOS THERAPEUTICS, INC.SEEL · Entity 93662 | Director | January 04, 2024 | January 08, 2024 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director · President & CEO | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SEELOS THERAPEUTICS, INC.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2034-01-04 | Direct | 1,666 |
Reported balance
After 2024-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-04 · Grant · Acquired 1,666 · Balance 1,666 F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 2,572,441 |
Ending reported balance
After 2026-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Grant · Acquired 221,667 · Balance 2,720,958 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. Row 2 · 2026-07-29 · Sale · Disposed 148,517 · Balance 2,572,441 F2: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 49,079 | $1.23 | $60,367.17 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,313,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 01:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-24-002512 · doc4.xml · derivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,148 Underlying: Common Stock · 85,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 01:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 45,000 | $24.95 | $1,122,750.00 |
DisclosureSEC source: 0001209191-24-002512 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,264,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 01:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 40,000 | $24.45 | $978,000.00 |
DisclosureSEC source: 0001209191-24-002512 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,309,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 01:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 85,000 | $1.23 | $104,550.00 |
DisclosureSEC source: 0001209191-24-002512 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,349,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 02:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-24-002458 · doc4.xml · derivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,148 Underlying: Common Stock · 35,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 02:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 35,000 | $23.95 | $838,250.00 |
DisclosureSEC source: 0001209191-24-002458 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,264,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 02:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 35,000 | $1.23 | $43,050.00 |
DisclosureSEC source: 0001209191-24-002458 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,299,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 39,552 | $18.58 | $734,876.16 |
DisclosureSEC source: 0001209191-24-000931 · doc4.xml · nonDerivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,264,882 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:45 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 1,666 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001104659-24-002384 · tm242318-2_4seq1.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,666 Underlying: Common Stock · 1,666 shares Expires 2034-01-04 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $17.40 | $0.00 |
DisclosureSEC source: 0001209191-24-000931 · doc4.xml · derivative · entry 6 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2034-01-03 F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 106,115 | $17.40 | $1,846,401.00 |
DisclosureSEC source: 0001209191-24-000931 · doc4.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,304,434 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000931 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,410,549 F4 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 108,525 | $17.40 | $1,888,335.00 |
DisclosureSEC source: 0001209191-24-000931 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250,549 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000931 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359,074 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.33% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 6,421 shares acquired on May 19, 2023 and 4,690 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| May 01, 2023 Filed May 1, 2023 23:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 45,000 | $22.45 | $1,010,250.00 |
DisclosureSEC source: 0001209191-23-026356 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,197,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 23:29 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 35,000 | $21.45 | $750,750.00 |
DisclosureSEC source: 0001209191-23-025277 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,242,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 23:09 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-23-024724 · doc4.xml · derivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 23:09 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 155,000 | $20.45 | $3,169,765.50 |
DisclosureSEC source: 0001209191-23-024724 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,277,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 23:09 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 125,000 | $2.15 | $268,750.00 |
DisclosureSEC source: 0001209191-23-024724 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,432,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 13, 2023 Filed Apr 13, 2023 21:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 54,336 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001209191-23-024228 · doc4.xml · derivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,336 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| April 13, 2023 Filed Apr 13, 2023 21:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 79,336 | $18.45 | $1,463,749.20 |
DisclosureSEC source: 0001209191-23-024228 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,307,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| April 13, 2023 Filed Apr 13, 2023 21:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 54,336 | $1.88 | $102,151.68 |
DisclosureSEC source: 0001209191-23-024228 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,387,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 200,000 | $17.57 | $3,514,000.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 9 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,332,963 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 8 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,532,963 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 22,000 | $17.85 | $392,700.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 7 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,232,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 67,970 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · derivative · entry 12 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,970 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person F5 · derivative.exercise_date: 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 67,970 | $17.45 | $1,186,076.50 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 6 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,254,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 67,970 | $9.49 | $645,035.30 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,322,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,530 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · derivative · entry 11 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,970 Underlying: Common Stock · 19,530 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person F5 · derivative.exercise_date: 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 115,852 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · derivative · entry 10 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,148 Underlying: Common Stock · 115,852 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person F4 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 65,382 | $17.45 | $1,140,915.90 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,254,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 88,000 | $16.95 | $1,491,600.00 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,320,345 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 19,530 | $9.49 | $185,339.70 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,408,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 115,852 | $1.23 | $142,497.96 |
DisclosureSEC source: 0001209191-23-022400 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,388,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 19:18 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001136261-23-000005 · ownership.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 5, 2023, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 04, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 28,619 | $8.42 | $240,971.98 |
DisclosureSEC source: 0001209191-23-001340 · doc4.xml · nonDerivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,272,963 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-001340 · doc4.xml · derivative · entry 6 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-01-03 F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 68,252 | $8.52 | $581,507.04 |
DisclosureSEC source: 0001209191-23-001340 · doc4.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,301,582 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 266,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001340 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,369,834 F4 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 66,127 | $9.40 | $621,593.80 |
DisclosureSEC source: 0001209191-23-001340 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,103,167 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 121,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001340 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,169,294 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 4,545 shares acquired on May 20, 2022 and 6,396 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 20:02 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001136261-22-000018 · ownership.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-01-05 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 5, 2022, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 26,432 | $4.62 | $122,115.84 |
DisclosureSEC source: 0001209191-22-001986 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036,686 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-22-001986 · doc4.xml · derivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2032-01-03 F4 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 173,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001986 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,063,118 F3 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 36,319 | $4.88 | $177,236.72 |
DisclosureSEC source: 0001209191-22-001986 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,785 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. F2 · balance_after: Includes 1,297 shares acquired on November 19, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 27,750 | $6.50 | $180,375.00 |
DisclosureSEC source: 0001209191-21-058253 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,924,807 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 55,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058253 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,952,557 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 28, 2021 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 2,876 shares acquired on May 20, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 23:19 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 5,611 | $6.68 | $37,481.48 |
DisclosureSEC source: 0001209191-21-004093 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894,181 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.